Ongoing important trialsPhase I/IINCT06445062
RAS(ON) inhibitor platform — GI solid tumor combinations
Pancreas · Colon · Multiple / solid tumors
RAS(ON) GI platform trial; subprotocol readouts must be read separately.
Registry checked: 2026-10-29
Clinical trials explorer
Filter by cancer type, molecular target, phase, and recruitment status.
Loading filters…
Ongoing important trialsPhase IINCT03897881
Interim analysis
KEYNOTE-942 — personalized mRNA-4157 + pembrolizumab (high-risk melanoma)
Melanoma
Phase IIb: primary Lancet HR 0.561; ~3y update ~49% relative RFS risk reduction — not a 49% cure rate.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT03221426
Final analysis
KEYNOTE-585 — perioperative pembrolizumab + chemotherapy (gastric/GEJ)
Gastric / esophageal
pathCR improved; EFS did not meet protocol success — OS not significant. Distinct from MATTERHORN.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT03656536
Interim analysis
FIGHT-302 — pemigatinib vs gem/cis in FGFR2-rearranged CCA (terminated)
Biliary tract
FGFR2-fusion 1L pemigatinib phase III terminated early — superiority not shown.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT04246177
Interim analysis
LEAP-012 — pembrolizumab + lenvatinib + TACE in intermediate HCC
Liver (HCC)
TACE + lenvatinib + pembrolizumab; terminated on CT.gov — read interim results separately.
Registry checked: 2026-10-29
Ongoing important trialsPhase IINCT03287375
Primary analysis
PIPAC — pressurized intraperitoneal aerosol chemotherapy for peritoneal metastasis
Peritoneal metastasis · Colon
PIPAC program registry completed; not a substitute for standard peritoneal CRC care.
Registry checked: 2026-10-29
Ongoing important trialsN/ANCT05384769
Interim analysis
CIRCULATE-Japan — ctDNA MRD-guided colorectal strategies
Colon · Rectum
ctDNA observational/platform (GALAXY); phase N/A — results are cohort-specific.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT05855200
AZUR-2 — perioperative dostarlimab in resectable dMMR/MSI-H colon cancer
Colon
Phase III; recruiting. Separate from AZUR-1 rectal AA — perioperative dostarlimab in colon.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT06783491
FOXHIPECT4 — neoadjuvant FOLFOX ± HIPEC in locally advanced colon cancer
Colon · Peritoneal metastasis
Phase III; recruiting. Neoadjuvant FOLFOX ± HIPEC — no results yet; do not confuse with PRODIGE 7.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT07271355
IMPACT — mitomycin PIPAC in unresectable appendiceal/CRC peritoneal metastases
Peritoneal metastasis · Colon
Phase III PIPAC; recruiting. Separate randomized comparison from the prior PIPAC program listing.
Registry checked: 2026-10-29
Ongoing important trialsPhase II/IIINCT05174169
CIRCULATE-US — ctDNA-guided adjuvant chemotherapy (stage II–III colon)
Colon
Phase II/III; recruiting. US randomized ctDNA trial separate from DYNAMIC / CIRCULATE-Japan.
Registry checked: 2026-10-29
Ongoing important trialsN/ANCT04264702
Primary analysis
BESPOKE CRC — ctDNA-guided therapy (observational)
Colon · Rectum
Observational; strong ctDNA MRD prognostic signal — separate from randomized CIRCULATE-US.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT04969731
Immuncell-LC + gemcitabine — resected PDAC adjuvant (phase III)
Pancreas
Phase III adjuvant cellular IO + gemcitabine; separate from PRODIGE-24 mFOLFIRINOX context.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT05314998
PREDICT-Panc — transcriptomic signature–guided adjuvant chemo
Pancreas
Phase III biomarker-guided adjuvant; recruiting — not yet a standard clinical predictor.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT06304974
BL-B01D1 (izalontamab brengitecan) — recurrent/metastatic ESCC (phase III)
Gastric / esophageal
Phase III BsADC; enrollment closed. EGFR×HER3 ADC — class distinct from zanidatamab.
Registry checked: 2026-10-29
Ongoing important trialsPhase IIINCT07582315
BL-B01D1 — post-platinum biliary tract cancer (phase III)
Biliary tract
Phase III; recruiting. Biliary BsADC — separate from ClarIDHy/FGFR context.
Registry checked: 2026-10-29